Phase 2 N=169 Study of VVN001 Ophthalmic Solution in Dry Eye Disease
Dry Eye
Primary: Inferior Corneal Fluorescein Staining — -0.69; -.97; -0.72 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=65 Sufentanil Infusion vs Sufentanil Bolus
Anesthesia
Primary: Time to Extubation — 230.5; 242.4 Minutes
Phase 2 N=25 A Study to Assess the Safety and Immunogenicity of PXVX0317 Chikungunya Virus Virus-Like Particle Vaccine
Chikungunya Virus
Primary: CHIKV SNA (Serum Neutralizing Antibody) Seroresponse Rate at Day 22 — 100.0 Percentage of participants
N/A N=50 The Right Ventricular Pulmonary Circulation Continuum in Mitral Valve Disease Study
Mitral Regurgitation · Pulmonary Hypertension
Primary: Impaired Post-operative Functional Capacity — 35 Participants
Phase 2 N=58 Study With CY, Pembrolizumab, GVAX Pancreas Vaccine, and SBRT in Patients With Locally Advanced Pancreatic Cancer
Pancreatic Cancer
Primary: Distant Metastasis Free Survival (DMFS) — 9.8 months
Phase 3 N=110 Evaluating the Pharmacodynamic Noninferiority of Efgartigimod PH20 SC Administered Subcutaneously as Compared to Efgartigimod Administered Intravenously in Patients With Generalized Myasthenia Gravis
Generalized Myasthenia Gravis
Primary: Percent Change From Baseline in Total IgG Levels at Day 29 (mITT Analysis Set) — -66.4; -62.2 percent — p=< 0.0001
Phase 2 N=49 A Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple Myeloma
Multiple Myeloma
Primary: Percentage of Participants With Adverse Events (AEs) — 100.0; 100.0; 100.0; 100.0 Percentage of Participants
N/A N=163 EFFICACY: Hopewell Hospitalist: A Video Game Intervention to Increase Advance Care Planning by Hospitalists
Advance Care Planning
Primary: Percentage of Patients With Advance Care Planning Bills — 5,298; 4,920 Participants — p=0.41
Phase 2 N=74 Posiphen® Dose-Finding, Biomarker Study in Early Alzheimer's and Parkinson's Patients
Alzheimer Disease · Parkinson Disease
Primary: Percentage of Participants With Treatment-Emergent Adverse Events — 3; 5; 4; 6 Participants
Phase 2 N=102 Randomized Trial of Maternal Progesterone Therapy
Congenital Heart Disease · Periventricular Leucomalacia · Brain Development
Primary: Motor Scale of the Bayley Scales of Infant and Toddler Development-III — 90.0; 87.5; 88.7 score on a scale
Phase 3 N=5,035 Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension
Dyslipidemia
Primary: Number of Participants Who Experienced an Adverse Event — 2144; 2084 Participants
N/A N=536 Mi Puente: My Bridge to Better Cardiometabolic Health and Well-Being
Type 2 Diabetes Mellitus · Cardiometabolic Conditions · Behavioral Health Concerns
Primary: Number of Patients With at Least 1 Hospital Readmission Within 30 Days After Enrollment — 43; 25 participants — p=0.01
N/A N=9 (SBRT) and (ART) for Pulmonary Metastases From Soft Tissue Sarcomas
Stage IV Adult Soft Tissue Sarcoma · Sarcoma,Soft Tissue
Primary: Number of Adverse Events of Grade ≥ 3 by CTCAE Criteria. — 8 events
Phase 3 N=54 A Study to Evaluate an Updated Dexamethasone Intravitreal (Into the Eye) Applicator in Adult Participants With Macular Edema Due to Diseases of the Retina
Macular Edema
Primary: Number of Participants Experiencing at Least One Adverse Events (AEs) — 13; 7 Participants
Phase 1 N=13 Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors
Non Small Cell Lung Cancer · Urothelial Carcinoma · Malignant Melanoma
Primary: Adverse Events Evaluated by CTCAE 4.0 — 1; 7; 2; 0 Participants